Debra Yu (LianBio)

Pfiz­er hands Lian­Bio $70M to tag along Per­cep­tive's Chi­na play, with an eye to beef­ing up re­gion­al port­fo­lio

When Per­cep­tive un­veiled its care­ful­ly cu­rat­ed syn­di­cate for Lian­Bio’s $310 mil­lion Se­ries A, Pfiz­er stood out as the on­ly phar­ma amid a mar­quee group of VCs. It turns out that the drug­mak­er wasn’t on­ly look­ing to share the fruits of Lian­Bio’s la­bor, it al­so wants to get down in­to the trench­es.

Pfiz­er has put an ad­di­tion­al $70 mil­lion on the ta­ble for Lian­Bio — which Per­cep­tive set out to shape in­to a “best-in-class sourc­ing and de­vel­op­ment en­gine” in Chi­na — to in-li­cense pro­grams that they can then co-de­vel­op. If a drug reach­es the mar­ket, Pfiz­er will be first in line to ne­go­ti­ate for stand­alone com­mer­cial deals.

Kon­stan­tin Poukalov

Hav­ing just re­cent­ly signed off on a $480 mil­lion col­lab­o­ra­tion to de­vel­op and com­mer­cial­ize CStone’s PD-1 in Chi­na, Doug Gior­dano, SVP of Pfiz­er world­wide busi­ness de­vel­op­ment, said the new deal ex­pands its “abil­i­ty to part­ner across the biotech ecosys­tem” and de­liv­er med­ical break­throughs to Chi­nese pa­tients.

“We’ve heard this re­peat­ed­ly from Big Phar­mas over the years that they get pro­grams com­ing down from glob­al but there’s of­ten not as much em­pha­sis and lit­tle ac­tiv­i­ty at the re­gion­al lev­el for busi­ness de­vel­op­ment,” De­bra Yu, Lian­Bio’s pres­i­dent/CBO and a Pfiz­er alum, told End­points News.

For Lian­Bio, the al­liance doesn’t just of­fer heavy­weight en­dorse­ment of its mod­el but al­so a way to tap in­to com­mer­cial in­fra­struc­ture that Pfiz­er has built over a decade.

Kon­stan­tin Poukalov, man­ag­ing di­rec­tor at Per­cep­tive and ex­ec­u­tive chair­man at Lian­Bio, not­ed that the in-kind help that Pfiz­er has com­mit­ted might just be as im­por­tant as the cash. From clin­i­cal tri­al ex­per­tise — Pfiz­er has 60-plus stud­ies un­der­way in the coun­try — and KOL net­work to cre­at­ing mar­ket ac­cess and deal­ing with the re­im­burse­ment process, the phar­ma gi­ant brings sig­nif­i­cant knowl­edge and ca­pac­i­ty to the pact.

Bing Li

In par­tic­u­lar, he adds, Lian­Bio will be pre­sent­ing to Pfiz­er as­sets that re­quire a large, spread-out sales force to cov­er vast ge­o­graph­i­cal re­gions. As­sets that are more tar­get­ed around spe­cif­ic cen­ters of care are more like­ly to be han­dled by the 30-plus Lian­Bio staffers (they’re still re­cruit­ing) CEO Bing Li is lead­ing in Shang­hai and Bei­jing.

As Yu scouts new deals with her New Jer­sey-based team, she be­lieves hav­ing Pfiz­er on board would con­vince biotech part­ners that by li­cens­ing Chi­na rights to Lian­Bio they will get the “best of both worlds.”

“It’s a very spe­cial kind of be­spoke cre­ative part­ner­ship that ben­e­fits all the three par­ties that are in­volved,” she said.

Pre­vi­ous­ly, Lian’s pitch­es main­ly re­volved around de­tailed mar­ket analy­ses and tai­lor-made de­vel­op­ment pro­pos­als that Bridge­Bio CEO Neil Ku­mar has praised as cre­ative. For $26.5 mil­lion in near-term pay­ments, he hand­ed over two tar­get­ed can­cer drug can­di­dates and gave away pref­er­en­tial fu­ture ac­cess to pro­grams across his sub­sidiaries’ port­fo­lio.

MyoKar­dia, mean­while, pro­vid­ed Lian with its first car­dio drug be­fore Bris­tol My­ers Squibb bought it for $13 bil­lion. Lian paid $40 mil­lion up­front for mava­camten and is on the hook for an­oth­er $147.5 mil­lion.

While Lian doesn’t en­vi­sion do­ing an­oth­er deal like the Pfiz­er one — elect­ing in­stead to pri­or­i­tize find­ing new drugs for its pipeline — Poukalov be­lieves oth­er phar­ma gi­ants are sim­i­lar­ly look­ing for ways to get their hands on drugs they may not oth­er­wise have ac­cess to.

“Just like you’ve seen in As­traZeneca’s case where they were able to do re­gion­al spe­cif­ic deals to dri­ve re­gion­al rev­enue, I think that’s top of mind for a lot of oth­er MNCs that are try­ing to evolve and re­al­ly kind of con­tin­ue to an­chor their po­si­tion in the mar­ket­place,” Poukalov said.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Vlad Coric, Biohaven CEO

Vlad Coric charts course for 'New Bio­haven' with neu­ro­science push and Big Phar­ma vets on board

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the “New Biohaven” post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Marc Dunoyer, Alexion CEO (AstraZeneca via YouTube)

Up­dat­ed: As­traZeneca nabs a small rare dis­ease gene ther­a­py play­er for 667% pre­mi­um

AstraZeneca is kicking off the fourth quarter with a little M&A Monday for a gene editing player recently overcoming a second clinical hold to its only program in human studies.

The Big Pharma and its subsidiary Alexion are buying out little LogicBio for $2.07 per share. That’s good for a massive 667% premium over its Friday closing price, when it headed into the weekend at 27 cents and just weeks after Nasdaq said LogicBio would have to delist, which has been put on hold as the biotech requests a hearing. It’s one of two biotech deals to commence October, alongside the news of Incyte buying a vitiligo-focused biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Dave Marek, Myovant CEO

My­ovant board balks as ma­jor­i­ty own­er Sum­it­o­mo swoops in with a $2.5B deal to buy them out

Three years after Sumitomo scooped up Roivant’s 46% stake in the publicly traded Myovant $MYOV as part of a 5-company, $3 billion deal, they’re coming back for the whole thing.

But these other investors at Myovant want more than what the Japanese pharma company is currently offering to pay at this stage.

Sumitomo is bidding $22.75 a share for the outstanding stock, which now represents 48% of the company after Sumitomo bumped its ownership since the original deal with Roivant. Myovant, however, created a special committee on the board, and they’re shaking their heads over the offer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Bob Duggan (Duggan Investments)

Biotech bil­lion­aire Bob Dug­gan flies the white flag as Sum­mit hunts a new own­er, or part­ner, for sole clin­i­cal-stage ef­fort

Bob Duggan’s Summit Therapeutics $SMMT is running out of moves for its sole clinical-stage candidate.

The biotech issued a terse statement in an SEC filing that it’s pulling the plug on the only active clinical trial for ridinilazole, which has been through a failed late-stage trial for C. difficile. A pediatric study is being curtailed as Summit says it decided a few days ago to either partner out the therapy or get a buyer — if they can find one.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Benjamine Liu, TrialSpark CEO

Paul Hud­son and Tri­alSpark's mu­tu­al de­sire to speed up de­vel­op­ment con­verges in three-year, six-drug goal

A unicorn startup that originally set out to hasten clinical studies for biopharma partners dug further into its revised path of internal drug development by linking arms with Sanofi in a pact that the biotech’s CEO said originated from the top.

TrialSpark and the Big Pharma on Tuesday committed to in-licensing and/or acquiring six Phase II/Phase III drugs within the next three years.

“I’ve known Paul Hudson for a while and we were discussing the opportunity to really re-imagine a lot of different parts of pharma,” TrialSpark CEO Benjamine Liu told Endpoints News, “and one of the things that we discussed was this opportunity to accelerate the development of new medicines in mutual areas of interest.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Ying Huang, Legend CEO

Lentivi­ral vec­tor ramp-up: J&J and Leg­end to in­vest $500M in New Jer­sey man­u­fac­tur­ing to sup­port Carvyk­ti

In response to a question on manufacturing scale at Legend Biotech’s R&D day yesterday, the company’s top exec said its partnership with Johnson & Johnson will be doubling its investment in its New Jersey manufacturing center and will be investing a total of $500 million.

With an eye on their BCMA-directed CAR-T therapy Carvykti (cilta-cel), approved in February as a fifth-line treatment for multiple myeloma, Legend CEO Ying Huang said that the ramp-up in production and the decision to manufacture its own lentiviral vectors — currently in shortage worldwide — means they won’t have to deal with that shortage.